It can pay to track what the big investors on Wall Street are trading in quarterly 13-F filings. This quarter, legendary hedge fund manager Stanley Druckenmiller added to his largest stock position, buying more Natera (NASDAQ: NTRA) for his family office. The innovative genetic testing company now accounts for 18% of Druckenmiller's 13-F portfolio, which includes all his U.S.-listed stocks.
Should you follow Druckenmiller into Natera stock? Let's take a closer look at the numbers and find out.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Modern medicines and treatments have led to a growing demand for advanced patient diagnostics. To tailor medicines for patients in prenatal care or with cancer, you need to understand more about their bodies and specific genetic makeup.
Natera specializes in bridging the gap between doctors and patients, using innovative cell-free DNA testing to help diagnose outcomes. Specifically, it serves the prenatal and cancer testing markets. For pregnant patients, a doctor can use a Natera test to diagnose any problems with the fetus, all with minimal physical intervention. Its cancer testing has a variety of use cases, but an important one is checking for residual disease evidence in patients, which can be invaluable for someone dealing with cancer in remission.
#innovative
Should you follow Druckenmiller into Natera stock? Let's take a closer look at the numbers and find out.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Modern medicines and treatments have led to a growing demand for advanced patient diagnostics. To tailor medicines for patients in prenatal care or with cancer, you need to understand more about their bodies and specific genetic makeup.
Natera specializes in bridging the gap between doctors and patients, using innovative cell-free DNA testing to help diagnose outcomes. Specifically, it serves the prenatal and cancer testing markets. For pregnant patients, a doctor can use a Natera test to diagnose any problems with the fetus, all with minimal physical intervention. Its cancer testing has a variety of use cases, but an important one is checking for residual disease evidence in patients, which can be invaluable for someone dealing with cancer in remission.
#innovative
1 day ago
